Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 8, 2025
Microbix Schedules Release of Results for Q2 Fiscal 2025
GlobeNewswire
·
May 8, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure …
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership …
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …
Syndax Announces Participation in May Investor Conferences
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …
Aptose Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
May 8, 2025
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …
Entrada Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 …
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
GlobeNewswire
·
May 8, 2025
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, …
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced …
Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2025 Outlook
GlobeNewswire
·
May 8, 2025
First Quarter Revenue was $559.2 million, a 14.0% increase over the prior year period Gross margin increased 25.9% to $183.6 million compared to Q1 2024 First Quarter Net income was $5.2 million compared to net loss of $11.2 million for the comparable …
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
GlobeNewswire
·
May 8, 2025
Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER) EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income(2) of € …
Privia Health Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Strong First Quarter Performance and Operating Execution Enters the State of Arizona Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged ARLINGTON, Va., May 08, 2025 (GLOBE NEWSWIRE) -- …
Dentsply Sirona Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impact GAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per share Adjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, …
Enovis Announces First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective …
NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
GlobeNewswire
·
May 8, 2025
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across multiple AAV programs LAUSANNE, …